This site is intended only for healthcare professionals resident in the Republic of Ireland
BOSULIF® (bosutinib) has been tested in a large number of patients and demonstrates efficacy in a wide range of patient types.1
Patient cohorts (N=574* including patients receiving 1 dose of BOSULIF)2-4
Primary cohort: imatinib resistant
Subgroup: imatinib intolerant
IMI-R/I + dasatinib resistant (n=38)
IMI-R/I + dasatinib intolerant (n=50)
IMI-R/I + nilotinib resistant (n=26)
IMI-R/I + nilotinib Intolerant or IMI-R/I + nilotinib-R/I + dasatinib-R/I (n=5)
Primary endpoint: 33% (95% CI, 27–40) MCyR at 24 weeks in imatinib-resistant patients (n=200)1,2
A Phase 3 study in patients with newly diagnosed CP Ph+ CML.5
A Phase 4 trial in Ph+ CML patients resistant or intolerant to prior therapy.6
Click here for BOSULIF® (bosutinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
The safety profile of BOSULIF is well established and includes long-term, cardiac, and vascular data1
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023